Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321,
are hereby summoned to the annual general meeting (the "Meeting"), to be held on
Thursday 26 April 2012 at 4.00 p.m. in Wallenbergsalen, at Kungliga
Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.

Participation, etc

Shareholders who wish to attend the Meeting must be recorded in the share
register maintained by Euroclear Sweden AB (the Swedish Central Securities
Depository) on Friday 20 April 2012, and must notify the company of their
intention to participate in the Meeting not later than Friday 20 April 2012 at
Swedish Orphan Biovitrum's web site www.sobi.com, by mail to Swedish Orphan
Biovitrum AB (publ), "Annual General Meeting", SE-112 76 Stockholm, Sweden or by
phone no. +46 8 697 34 27. The notification shall set forth the name, address,
telephone number (daytime), personal/corporate identity number, the number of
shares held and, when applicable, information about representatives and
assistants.

As per the day of this notice there are 267,295,132 shares outstanding in the
company, whereof 265,226,598 common shares representing one vote each and
2,068,534 series C shares representing 1/10 vote each, altogether representing
265,433,451.4 votes. The company holds 2,068,534 own series C shares, which
cannot be represented at the general meeting.

Nominee shares

Shareholders, whose shares have been registered in the name of a nominee through
the trust department of a bank or similar institution, must, in order to be able
to participate in the Meeting, temporarily re-register their shares in their own
names in the shareholders' register maintained by Euroclear Sweden AB as per
Friday 20 April 2012. Shareholders who wish to re-register their shares in their
own name should inform their nominee of such re-registration well in advance of
such date.

Proxy, etc

Shareholders represented by proxy shall issue a written and dated power of
attorney for the proxy. If the power of attorney is issued on behalf of a legal
entity, a certified copy of a registration certificate for the legal entity
shall be appended. The power of attorney is valid for one year from the issue
thereof or such longer period of time stated in the power of attorney, however
not more than five years. A registration certificate shall evidence the
circumstances prevailing at the day of the Meeting and should not be older than
one year at the time of the Meeting.

The power of attorney in original and, when applicable, the registration
certificate, should be submitted to the company by mail at the address indicated
above well before the Meeting. A proxy form is held available at the company's
web site, www.sobi.com, and will also be sent to shareholders who so request and
who inform the company of their postal address.



Attachment:The complete Notice of annual general meeting in Swedish Orphan
Biovitrum AB (publ)





About Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 45 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.



The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 26 March 2012 at 08.30 CET.